EverBridge Medical Secures $138.9M to Accelerate Global MedTech Innovations

EverBridge Medical is thrilled to announce that it has successfully raised $138,900,000 in its latest round of funding—a milestone that marks a new chapter in the company’s ambitious journey. As a leading Asia-based MedTech group, EverBridge is dedicated to providing cutting-edge, high-quality, and affordable medical technologies to global customers. This robust funding injection will significantly accelerate the company’s vision of benefiting global patients and bridging the world through medtech innovation. With a fast-growing product portfolio spanning Peripheral Vascular, Neuroscience, and Oncology Devices, EverBridge has already made significant strides by improving the lives of millions of patients worldwide. The newly raised funds are set to fortify EverBridge’s strategic initiatives, including expanding its five specialized R&D and Lean Manufacturing centers. These centers have been crucial in enabling the company to deliver top-notch OEM/ODM services across a range of critical areas such as Balloon, Catheters, Stents, Surface Processing, and Active Devices. Moreover, the funding will facilitate deeper collaboration efforts, both regionally and globally. EverBridge is actively pursuing strategic partnerships, including in/out-licensing arrangements, distribution collaborations, and equity investments, to bridge medtech innovations across Asia and beyond. This capital infusion not only underscores the market’s confidence in EverBridge’s pioneering capabilities but also reinforces its commitment to continuous innovation and expansive global outreach. By investing in research and the development of more sophisticated, accessible technologies, EverBridge Medical is well-positioned to drive the next wave of breakthroughs in the MedTech industry, ensuring that patients worldwide can benefit from state-of-the-art healthcare solutions.